EMA Authorised: Teysuno (tegafur;gimeracil;oteracil) — Nordic Group B.V.

View source ↗

Summary

The EMA authorised Teysuno, a fixed-dose combination of tegafur, gimeracil and oteracil, for stomach cancer. The marketing authorisation holder is Nordic Group …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stomach Cancer

Drugs mentioned

• Teysuno (tegafur; gimeracil; oteracil)

Snippet

Status: Authorised. Therapeutic area: Stomach Neoplasms. MAH: Nordic Group B.V.. Decision date: 30/10/2025